Tags

Type your tag names separated by a space and hit enter

Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels.
Thromb Haemost. 2009 Feb; 101(2):312-6.TH

Abstract

Recent reports have described the factor XIII A subunit (FXIII-A) Val34Leu polymorphism as a protective factor against venous and arterial thrombosis. The aim of this study was to investigate the association between the FXIII-A Val34Leu polymorphism, its interaction with fibrinogen concentration, and thrombosis in patients with antiphospholipid antibodies (aPL). We included 172 consecutive patients with aPL: 88 with primary antiphospholipid syndrome (APS), 38 with APS associated with systemic lupus erythematosus (APS-SLE), 32 with SLE and aPL but without APS (SLE-aPL), and 14 asymptomatic individuals with aPL (A-aPL). The FXIII-A Val34Leu polymorphism was assessed by polymerase chain reaction techniques. We found no significant differences in FXIII-A Leu34 allele frequencies between primary APS (allele frequency 0.22), APS-SLE (0.23), SLE-aPL (0.22) and A-aPL (0.32) patients, or between patients with (0.21) and without thrombosis (0.26). FXIII-A Leu34 allele frequencies were significantly lower in patients with thrombosis and those in the upper fibrinogen tertile (>3.40 g/l) (allele frequency 0.07) compared with patients without thrombosis in the upper fibrinogen tertile (0.29) and patients with (0.29) and without (0.25) thrombosis in the mid- and lower fibrinogen tertiles. The FXIII-A Leu34 allele had a protective effect against thrombosis in patients in the upper fibrinogen tertile (odds ratio [OR] = 0.20, 95% confidence interval [CI] 0.07-0.60) but not in those in the other tertiles (OR = 1.20, 95% CI 0.67-2.16). The FXIII-A Leu34 allele seems to have a protective effect on the development of thrombosis in patients with aPL, but only in those with high plasma fibrinogen values.

Links

Aggregator Full Text

Authors+Show Affiliations

de la Red G
Department of Hemotherapy and Hemostasis, Hospital Clinic, Villarroel 170, 08036 Barcelona, Catalonia, Spain.
Tàssies D
No affiliation info available
Espinosa G
No affiliation info available
Monteagudo J
No affiliation info available
Bové A
No affiliation info available
Plaza J
No affiliation info available
Cervera R
No affiliation info available
Reverter JC
No affiliation info available

MeSH

AdultAntiphospholipid SyndromeCase-Control StudiesFactor XIIIFemaleFibrinogenGene FrequencyGenetic Predisposition to DiseaseHumansLeucineMaleOdds RatioPolymorphism, GeneticProtein SubunitsRisk AssessmentRisk FactorsThrombosisUp-RegulationValine

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19190815

Citation

de la Red, Gloria, et al. "Factor XIII-A Subunit Val34Leu Polymorphism Is Associated With the Risk of Thrombosis in Patients With Antiphospholipid Antibodies and High Fibrinogen Levels." Thrombosis and Haemostasis, vol. 101, no. 2, 2009, pp. 312-6.
de la Red G, Tàssies D, Espinosa G, et al. Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels. Thromb Haemost. 2009;101(2):312-6.
de la Red, G., Tàssies, D., Espinosa, G., Monteagudo, J., Bové, A., Plaza, J., Cervera, R., & Reverter, J. C. (2009). Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels. Thrombosis and Haemostasis, 101(2), 312-6.
de la Red G, et al. Factor XIII-A Subunit Val34Leu Polymorphism Is Associated With the Risk of Thrombosis in Patients With Antiphospholipid Antibodies and High Fibrinogen Levels. Thromb Haemost. 2009;101(2):312-6. PubMed PMID: 19190815.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels. AU - de la Red,Gloria, AU - Tàssies,Dolores, AU - Espinosa,Gerard, AU - Monteagudo,Joan, AU - Bové,Albert, AU - Plaza,Joan, AU - Cervera,Ricard, AU - Reverter,Joan-Carles, PY - 2009/2/5/entrez PY - 2009/2/5/pubmed PY - 2009/3/21/medline SP - 312 EP - 6 JF - Thrombosis and haemostasis JO - Thromb Haemost VL - 101 IS - 2 N2 - Recent reports have described the factor XIII A subunit (FXIII-A) Val34Leu polymorphism as a protective factor against venous and arterial thrombosis. The aim of this study was to investigate the association between the FXIII-A Val34Leu polymorphism, its interaction with fibrinogen concentration, and thrombosis in patients with antiphospholipid antibodies (aPL). We included 172 consecutive patients with aPL: 88 with primary antiphospholipid syndrome (APS), 38 with APS associated with systemic lupus erythematosus (APS-SLE), 32 with SLE and aPL but without APS (SLE-aPL), and 14 asymptomatic individuals with aPL (A-aPL). The FXIII-A Val34Leu polymorphism was assessed by polymerase chain reaction techniques. We found no significant differences in FXIII-A Leu34 allele frequencies between primary APS (allele frequency 0.22), APS-SLE (0.23), SLE-aPL (0.22) and A-aPL (0.32) patients, or between patients with (0.21) and without thrombosis (0.26). FXIII-A Leu34 allele frequencies were significantly lower in patients with thrombosis and those in the upper fibrinogen tertile (>3.40 g/l) (allele frequency 0.07) compared with patients without thrombosis in the upper fibrinogen tertile (0.29) and patients with (0.29) and without (0.25) thrombosis in the mid- and lower fibrinogen tertiles. The FXIII-A Leu34 allele had a protective effect against thrombosis in patients in the upper fibrinogen tertile (odds ratio [OR] = 0.20, 95% confidence interval [CI] 0.07-0.60) but not in those in the other tertiles (OR = 1.20, 95% CI 0.67-2.16). The FXIII-A Leu34 allele seems to have a protective effect on the development of thrombosis in patients with aPL, but only in those with high plasma fibrinogen values. SN - 0340-6245 UR - https://www.unboundmedicine.com/medline/citation/19190815/Factor_XIII_A_subunit_Val34Leu_polymorphism_is_associated_with_the_risk_of_thrombosis_in_patients_with_antiphospholipid_antibodies_and_high_fibrinogen_levels_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=19190815.ui DB - PRIME DP - Unbound Medicine ER -